ADCs

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

ADCs
Nov 16, 2024, 12:07 | Insight
Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective in Clinical Practice
"Doctors Roberto Paz-Manrique, Joseph Pinto, and Henry Gómez Moreno from Peru have published a narrative…
Nov 16, 2024, 09:57 | Blog
Targeting expression in metastatic breast cancer - ASCO
ASCO posted the following on X: “Though ADCs have emerged as a cutting-edge approach to…
Nov 13, 2024, 16:00 | Insight
Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases
Elisabetta Bonzano, Radiation Oncologist at Fondazione IRCCS Policlinico San Matteo and University of Pavia, shared…
Nov 12, 2024, 18:55 | Insight
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by…
Nov 12, 2024, 18:43 | Insight
Paolo Tarantino: Could ADCs be safely administered subcutaneously?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Could ADCs…
Nov 7, 2024, 16:00 | Blog
Lavinia Woodward: Next-Generation Drug Conjugates - Potential Beyond Oncology
Lavinia Woodward, Senior Product Development Producer at Beacon, shared a post on LinkedIn: "Next-Generation Drug…
Oct 30, 2024, 10:02 | Insight
Paper Alert ! Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer Authors: Chrysanthi Koukoutzeli, Dario…
Oct 28, 2024, 08:58 | Insight
Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…
Oct 26, 2024, 15:59 | Insight
Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs
Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post…
Oct 17, 2024, 12:51 | Insight
What do you envision for the bladder cancer landscape with the addition of ADCs to the treatment armamentarium?
Uromigos made the following post on X: “The Uromigos Live24 panel session on whether antibody…
Oct 11, 2024, 08:15 | Insight
Managing ADC Toxicities on Lung Cancer Considered
IASLC shared a post on X: “Anti Drug Conjugates represent a new way of treating…
Sep 23, 2024, 16:12 | Insight
Giuseppe Banna: How ADCs are revolutionizing patient outcomes in real-time
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn: “Join…
Sep 21, 2024, 01:25 | Insight
Paolo Tarantino: 10 facts to know to prepare for the rise of ADCs
Paolo Tarantino shared on X: “ADCs are among the most rapidly expanding treatment modalities in…
Sep 15, 2024, 15:20 | Insight
Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar…
Sep 11, 2024, 06:39 | Blog
Stephen Liu: Looking forward to discussing updates in ADCs for lung cancer at WCLC24
Stephen Liu shared a post on X: “Looking forward to WCLC24 - join us for lunch…
Jul 25, 2024, 18:24 | Insight
Myeloma Paper of the Day, July 25th, suggested by Robert Orlowski
Robert Orlowski shared on X: “Myeloma Paper of the Day: Retrospective study finds that, among BCMA-directed therapies,…
Jul 21, 2024, 09:23 | Blog
Paolo Tarantino: We just see the tip of the iceberg of how ADCs work
Paolo Tarantino shared on X:            . "On my way to…
Jul 20, 2024, 10:53 | Insight
Understanding the mechanisms underlying innate immune cell dysfunction in the TME
Alexander Ariel Padrón González, Internal Clinician at 3cert Limited, shared a post on LinkedIn about a…
Jul 14, 2024, 06:24 | Blog
Dr. Paolo Tarantino reviewed key ongoing clinical trials at Harvard Breast Cancer Course - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X:   . "Dr. Paolo Tarantino reviewed key…
Jul 12, 2024, 14:35 | Blog
Evolving management of NSCLC - FlorezLab
FlorezLab shared on X: "The treatment landscape of advanced NSCLC is evolving! Join Dr. Narjust…
Jul 11, 2024, 06:26 | Insight
The Role of Antibody-Drug conjugates (ADCs) in Bladder Cancer
Bladder Cancer Advocacy Network shared on X: "Get practical guidance on using antibody–drug conjugates in…
Jul 3, 2024, 08:52 | Insight
Paolo Tarantino: More data supporting that ADCs act in part by extending the half life of payloads
Paolo Tarantino shared a post by Raffaele Colombo on X, adding the following: “More data…
Jun 28, 2024, 06:15 | Blog
The American Journal of Managed Care highlights the latest research from Erika Hamilton
Sarah Cannon Research Institute shared the following post on LinkedIn: “AJMC - The American Journal…
Jun 28, 2024, 01:53 | Blog
Julia Lai-Kwon: Hope Rugo highlighting the different toxicities between different ADCs
Julia Lai-Kwon, Medical Oncologist and PhD candidate at Peter Mac Cancer Centre, recently shared a…
Jun 24, 2024, 13:33 | Blog
Erika Hamilton's insights into the future of ADCs in oncology - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared the following post on LinkedIn: “We are thrilled to share…
Jun 23, 2024, 13:45 | Insight
START Midwest team has successfully dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial
The START Center for Cancer Research shared on LinkedIn:          . "We…
Jun 11, 2024, 12:56 | Insight
Radiopharmaceuticals are revolutionizing the way we approach diagnosis, medical treatment, and patient care - Allucent
Allucent recently shared a post on LinkedIn: "Radiopharmaceuticals are gaining significant attention as this treatment…
Jun 5, 2024, 04:25 | Blog
Giuseppe Curigliano: Excited to see NBC News highlight the groundbreaking results of DESTINY-06
Giuseppe Curigliano reposted Erika Hamilton's post on LinkedIn, adding:    . "Excited to see NBC…
Jun 4, 2024, 09:59 | Blog
Marco Gymnopoulos: Looking for an associate director for my solid tumor ADC portfolio team at AstraZeneca
Marco Gymnopoulos, Director ADC Portfolio at AstraZeneca, shared a post on LinkedIn: ''Hiring: I am…
Jun 3, 2024, 11:57 | Societies
Tanja Obradovic: Very dynamic day at ASCO2024
Tanja Obradovic shared a post on LinkedIn: "Very dynamic ASCO2024 day as we learned quite…
Jun 1, 2024, 08:47 | Blog
Paolo Tarantino: ADCs keep shortening the distance between oncology fields
Paolo Tarantino shared a post on X: "ADCs keep shortening the distance between oncology fields.…
Jun 1, 2024, 00:10 | Insight
Margaret Gatti-Mays: My top 10 list of abstracts for breast cancer
Margaret Gatti-Mays, Co-Director of the Division of Medical Oncology at the Ohio State University, shared on…
May 27, 2024, 06:53 | Blog
Aakash Desai: Top picks to watch out in developmental therapeutics on ASCO24, Abstract release day
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: ''T-9 ASCO24,…
May 26, 2024, 13:52 | Blog
Charu Aggarwal: Catch a preview of what is coming at the Annual Meeting ASCO Daily News Podcast
Charu Aggarwal, Associate Professor of Lung Cancer at Penn Medicine shared a post by ASCO on…
May 19, 2024, 13:37 | Insight
Charles Chen: Check out our recent publication about PK/PD framework for ADC!
Charles Chen, Senior Director of Clinical Pharmacology and Translational Sciences at Zymeworks, shared a post…
May 15, 2024, 08:32 | Blog
Tanja Obradovic: Private Biotech investment is on the steady rise reaching $3.1 billion in April
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: “Private Biotech investment is…
May 13, 2024, 14:12 | Blog
Raffaele Colombo: Personal selection of 30 new ADCs that will be presented at ASCO24
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on X: "Personal selection of…
May 3, 2024, 23:43 | Blog
Tanja Obradovic: All eyes are on ADCs coming from China's biotech innovation engine and CAR-T cell therapy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on…
May 2, 2024, 15:20 | Blog
Paolo Tarantino: Impressive to think at the journey of ADCs over the last five years
Paolo Tarantino shared on LinkedIn: "Impressive to think at the journey of ADCs over the last…
Apr 22, 2024, 19:23 | Insight
New Paper Alert! A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners Foundation
A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners…
Apr 13, 2024, 14:18 | Insight
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center,…
Apr 8, 2024, 15:17 | Blog
Petros Grivas: Can’t wait to join Paolo Tarantino and Helena Yu to review ADCs across solid tumors
Petros Grivas, Associate Professor at the University of Washington, recently shared a post by Paolo…
Apr 8, 2024, 15:15 | Blog
Raffaele Colombo: AACR Annual Meeting 2024 has started!
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on LinkedIn: "AACR Annual Meeting…
Apr 2, 2024, 05:10 | Blog
Chul Kim: March has been fruitful and rewarding, as we launched two IITs of ADC back to back!
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared on X/Twitter: "March has been fruitful…
Mar 16, 2024, 14:58 | Blog
Lung Cancer Research Foundation has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca
Haichuan Hu, Director of Early Clinical Development - Hematology, Oncology and Cell Therapy at Bristol…
Feb 23, 2024, 18:07 | Insight
Estela Rodriguez: Great session on ADCs for lung cancer at WCLC24
Estela Rodriguez recently tweeted: "Saving the best for last! Great session on ADCs for lung…
Feb 19, 2024, 07:17 | Career
Paolo Tarantino: Honored to be awarded a Terri Brodeur Foundation 2024 Grant
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared on X/Twitter: "Honored…
Feb 13, 2024, 07:45 | Blog
Christopher R. Flowers: Congratulations to Dr. Funda Meric-Bernstam on the ESMO Targeting Anticancer Therapy Honorary Award!
Christopher R. Flowers shared a post by ESMO on LinkedIn: "Congratulations to Dr. Funda Meric-Bernstam,…
Feb 8, 2024, 17:54 | Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Feb 8, 2024, 05:08 | Insight
Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X: "From no…
Feb 1, 2024, 17:31 | Insight
Paolo Tarantino: Any agnostic approval should not stop efforts in biomarker discovery for ADCs
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Of…
Dec 29, 2023, 15:40 | Insight
Balazs Halmos: The docetaxel enigma continues
Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post…
Nov 5, 2023, 18:42 | Blog
A strategic collaboration with Jiangsu Hengrui Pharmaceuticals and EMD Serono
EMD Serono posted on LinkedIn. "News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This…
Jun 28, 2023, 17:38 | Positive
ADCs keep showing impressive activity across cancers - Paolo Tarantino
ADCs keep showing impressive activity across cancers. 1L EV+pembro led to 64% ORR among patients…
Jun 19, 2023, 18:11 | Drugs
Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing oncology therapeutics - Antonio Passaro
I am delighted to share the our recent publication in JCO titled "Antibody-Drug Conjugates in…
All: 55 Posts: 1 - 100
Special Coverage